Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs ...

Barbara Schädler (1962), Head of Group Communications and member of Roche’s enlarged Corporate Executive Committee, will retire from the company at the end of the year. Barbara Schädler joined Roche ...

About the Phase 1 study The Phase 1 clinical pharmacology study is a double-blind, randomized, placebo-controlled, two-part trial to assess the safety, tolerability, and immunogenicity of up to 3 ...

Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced ...

Japanese Ministry of Health, Labour and Welfare decision adds to similar designations in the US and Europe, underscoring global regulatory recognition of the potential for riliprupart to address ...

Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi.com) ...

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy ...

Some of the latest technologies and solutions from Smith+Nephew for joint repair include: REGENETEN◊ Bioinductive Implant: ...

Following a successful 2025 kickoff in Illinois on March 25 and its third annual event in Massachusetts on June 4-5 featuring ...

As an innovative sleep product, the QuietLab stop snoring device is positioned as an ideal option for anyone seeking a ...

Discover why VigRX Organic Bio Maca is being recognized in 2025 as the best maca root supplement for men and women. Explore ...

Aryna Sabalenka becomes first-ever current athlete shareholder in Prenetics, listed on the NASDAQ: (PRE) In just six months, ...